

**DOCKET NO.: RTS-0242US.P1****PATENT****In the Claims**

This listing of the claims will replace all prior versions, and listings, of the claims in the application:

1. (currently amended) An antisense compound 8 to 50 nucleobases in length targeted to nucleobases 436 to 477 96-523 of a coding region of a nucleic acid molecule encoding human superoxide dismutase 1, soluble (SEQ ID NO: 3), wherein said compound specifically hybridizes with a nucleic acid molecule (SEQ ID NO: 3) encoding human superoxide dismutase 1, soluble and inhibits the expression of human superoxide dismutase 1, soluble (SEQ ID NO: 3).
2. (original) The compound of claim 1 which is an antisense oligonucleotide.
3. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
4. (original) The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.
5. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
6. (original) The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
7. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
8. (original) The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.

**DOCKET NO.: RTS-0242US.P1****PATENT**

9. (original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

10. (canceled)

11. (new) An antisense compound of claim 1, wherein the antisense compound is targeted to nucleobases 440 to 459 of a coding region of a nucleic acid molecule encoding human superoxide dismutase 1, soluble (SEQ ID NO: 3).

12. (new) An antisense compound of claim 1, wherein the antisense compound is targeted to nucleobases 452 to 471 of a coding region of a nucleic acid molecule encoding human superoxide dismutase 1, soluble (SEQ ID NO: 3).

**DOCKET NO.: RTS-0242US.P1****PATENT****In the Sequence Listing**

The following sequences will be added to the end of the sequence listing as filed:

&lt;210&gt; 340

&lt;211&gt; 21

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 340

cgagaggcgg acgggaccgt t

21

&lt;210&gt; 341

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Antisense Oligonucleotide

&lt;400&gt; 341

ttgctctccg cctgccctgg c

21